SKIN SkinHealth Systems Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1818093 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.4%
TTM net income YoY-55.7%
TTM EPS YoY117.5%
Revenue 3-yr CAGR-10.3%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin2.4%
Net margin-6.3%
FCF margin7.9%
EBITDA margin3.2%
Returns
ROE-30.1%
ROA-4.1%
ROIC (approx.)7.1%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets85.7%
Debt / equity0.00x
Current ratio2.89x
Interest coverage0.27x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $69.17M | $72.11M | $64.91M | $82.37M | $70.66M | $78.19M | $69.58M | $83.50M |
| Cost of revenue | $22.02M | $22.77M | $20.47M | $29.33M | $25.02M | $29.07M | $21.00M | $31.15M |
| Gross profit | $47.15M | $49.34M | $44.44M | $53.04M | $45.63M | $49.11M | $48.58M | $52.35M |
| R&D expense | $1.66M | $1.41M | $1.10M | $1.68M | $1.70M | $1.25M | $998,000 | $1.22M |
| SG&A expense | $20.50M | $23.34M | $21.94M | $27.68M | $29.25M | $27.45M | $33.56M | $31.76M |
| Operating income | $4.98M | $3.57M | -$1.80M | $162,000 | -$6.24M | -$2.70M | -$12.02M | -$7.16M |
| Interest expense | $6.27M | $6.29M | $6.35M | $6.37M | $6.31M | $4.14M | $2.50M | $2.46M |
| Pretax income | -$108,000 | -$1.46M | -$6.81M | -$4.81M | -$10.64M | $18.72M | -$9.20M | -$11.72M |
| Income tax | $780,000 | $1.21M | -$184,000 | $3.30M | $386,000 | -$993,000 | $892,000 | -$1.39M |
| Net income | -$888,000 | -$2.67M | -$6.63M | -$8.10M | -$11.03M | $19.71M | -$10.10M | -$10.33M |
| EBITDA | $5.53M | $4.10M | -$1.24M | $806,000 | -$5.61M | -$1.99M | -$10.17M | -$5.70M |
| EPS (basic) | -0.14 | -0.02 | -0.05 | — | -1.74 | 0.16 | -0.08 | — |
| EPS (diluted) | -0.14 | -0.02 | -0.05 | — | -1.74 | 0.03 | -0.08 | — |
| Weighted avg. shares (diluted) | 6.51M | 129.60M | 131.40M | — | 6.35M | 140.29M | 125.08M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $112.39M | $206.07M | $204.36M | $232.67M | $219.40M | $212.00M | $373.03M | $370.06M |
| Receivables | $18.47M | $17.64M | $18.61M | $21.74M | $22.21M | $25.05M | $23.26M | $27.64M |
| Inventory | $46.25M | $46.84M | $47.69M | $48.01M | $56.15M | $59.19M | $65.63M | $69.11M |
| Current assets | $201.59M | $295.24M | $277.69M | $309.52M | $308.37M | $306.11M | $469.37M | $477.12M |
| PP&E, net | $1.85M | $2.09M | $2.34M | $2.54M | $3.05M | $3.70M | $4.22M | $5.98M |
| Goodwill | $126.12M | $126.35M | $126.25M | $126.62M | $126.50M | $126.27M | $124.26M | $123.50M |
| Intangibles | $27.61M | $30.22M | $32.80M | $35.76M | $37.98M | $43.49M | $45.65M | $47.51M |
| Total assets | $389.06M | $486.57M | $473.23M | $499.80M | $503.64M | $507.56M | $673.82M | $685.68M |
| Current liabilities | $69.84M | $168.20M | $155.20M | $186.28M | $61.90M | $59.44M | $62.80M | $68.15M |
| Long-term debt | — | — | — | — | $363.39M | $363.10M | — | $552.20M |
| Total debt | — | — | — | — | $363.39M | $363.10M | — | $552.20M |
| Total liabilities | $333.31M | $431.00M | $417.99M | $438.75M | $437.98M | $433.56M | $627.76M | $633.88M |
| Shareholders' equity | $55.76M | $55.57M | $55.24M | $61.06M | $65.66M | $74.00M | $46.06M | $51.80M |
| Net debt | — | — | — | — | $143.99M | $151.10M | — | $182.13M |
| Shares outstanding | 6.51M | 130.10M | 129.14M | 6.38M | 127.30M | 126.76M | 125.25M | 124.92M |
| Cash flow statement | ||||||||
| Operating cash flow | $11.26M | $2.67M | -$5.55M | $15.20M | $9.65M | $9.65M | $3.00M | $16.47M |
| Capital expenditure | $93,000 | $427,000 | $224,000 | $139,000 | $27,000 | $92,000 | $45,000 | $74,000 |
| Free cash flow | $11.17M | $2.24M | -$5.78M | $15.06M | $9.62M | $9.55M | $2.95M | $16.40M |
| Investing cash flow | -$1.06M | -$1.21M | -$1.65M | -$1.38M | -$1.08M | -$1.55M | -$1.15M | -$862,000 |
| Financing cash flow | -$103.51M | -$224,000 | -$20.91M | -$512,000 | -$803,000 | -$173.36M | -$250,000 | -$770,000 |
| Depreciation & amortization | $552,000 | $529,000 | $563,000 | $644,000 | $637,000 | $711,000 | $1.86M | $1.45M |
| Stock-based compensation | $1.44M | $2.90M | $2.08M | $3.58M | $2.46M | $5.31M | $3.48M | $5.85M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.